|
1
|
Martin RM, Donovan JL, Turner EL, Metcalfe
C, Young GJ, Walsh EI, Lane JA, Noble S, Oliver SE, Evans S, et al:
Effect of a low-intensity PSA-based screening intervention on
prostate cancer mortality: The CAP randomized clinical trial. JAMA.
319:883–895. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Xuan W, Khan F, James CD, Heimberger AB,
Lesniak MS and Chen P: Circadian regulation of cancer cell and
tumor microenvironment crosstalk. Trends Cell Biol. 31:940–950.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhu X, Maier G and Panda S: Learning from
circadian rhythm to transform cancer prevention, prognosis, and
survivorship care. Trends Cancer. 10:196–207. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Siegel RL, Giaquinto AN and Jemal A:
Cancer statistics, 2024. CA Cancer J Clin. 74:12–49.
2024.PubMed/NCBI
|
|
5
|
Wang C, Barnoud C, Cenerenti M, Sun M,
Caffa I, Kizil B, Bill R, Liu Y, Pick R, Garnier L, et al:
Dendritic cells direct circadian anti-tumour immune responses.
Nature. 614:136–143. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jiang M, Jia K, Wang L, Li W, Chen B, Liu
Y, Wang H, Zhao S, He Y and Zhou C: Alterations of DNA damage
response pathway: Biomarker and therapeutic strategy for cancer
immunotherapy. Acta Pharm Sin B. 11:2983–2994. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shang S, Liu J, Verma V, Wu M, Welsh J, Yu
J and Chen D: Combined treatment of non-small cell lung cancer
using radiotherapy and immunotherapy: Challenges and updates.
Cancer Commun (Lond). 41:1086–1099. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Spaich S, Will RD, Just S, Spaich S, Kuhn
C, Frank D, Berger IM, Wiemann S, Korn B, Koegl M, et al: F-box and
leucine-rich repeat protein 22 is a cardiac-enriched F-box protein
that regulates sarcomeric protein turnover and is essential for
maintenance of contractile function in vivo. Circ Res.
111:1504–1516. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hughes DC, Baehr LM, Driscoll JR, Lynch
SA, Waddell DS and Bodine SC: Identification and characterization
of Fbxl22, a novel skeletal muscle atrophy-promoting E3 ubiquitin
ligase. Am J Physiol Cell Physiol. 319:C700–C719. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Beisaw A, Kuenne C, Guenther S, Dallmann
J, Wu CC, Bentsen M, Looso M and Stainier DYR: AP-1 contributes to
chromatin accessibility to promote sarcomere disassembly and
cardiomyocyte protrusion during zebrafish heart regeneration. Circ
Res. 126:1760–1778. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Haddad SA, Ruiz-Narváez EA, Haiman CA,
Sucheston-Campbell LE, Bensen JT, Zhu Q, Liu S, Yao S, Bandera EV,
Rosenberg L, et al: An exome-wide analysis of low frequency and
rare variants in relation to risk of breast cancer in African
American Women: the AMBER Consortium. Carcinogenesis. 37:870–877.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tekcham DS, Chen D, Liu Y, Ling T, Zhang
Y, Chen H, Wang W, Otkur W, Qi H, Xia T, et al: F-box proteins and
cancer: An update from functional and regulatory mechanism to
therapeutic clinical prospects. Theranostics. 10:4150–4167. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu J, Tan Z, Yang S, Song X and Li W: A
circadian rhythm-related gene signature for predicting relapse risk
and immunotherapeutic effect in prostate adenocarcinoma. Aging
(Albany NY). 14:7170–7185. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z,
Feng T, Zhou L, Tang W, Zhan L, et al: clusterProfiler 4.0: A
universal enrichment tool for interpreting omics data. Innovation
(Camb). 2:1001412021.PubMed/NCBI
|
|
15
|
Liu J, Lichtenberg T, Hoadley KA, Poisson
LM, Lazar AJ, Cherniack AD, Kovatich AJ, Benz CC, Levine DA, Lee
AV, et al: An integrated TCGA pan-cancer clinical data resource to
drive high-quality survival outcome analytics. Cell.
173:400–16.e11. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ukimura O, Coleman JA, de la Taille A,
Emberton M, Epstein JI, Freedland SJ, Giannarini G, Kibel AS,
Montironi R, Ploussard G, et al: Contemporary role of systematic
prostate biopsies: Indications, techniques, and implications for
patient care. Eur Urol. 63:214–230. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nguyen L, J WMM, Van Hoeck A and Cuppen E:
Pan-cancer landscape of homologous recombination deficiency. Nat
Commun. 11:55842020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gonzalez D and Stenzinger A: Homologous
recombination repair deficiency (HRD): From biology to clinical
exploitation. Genes Chromosomes Cancer. 60:299–302. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Antonarakis ES, Lu C, Wang H, Luber B,
Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, et
al: AR-V7 and resistance to enzalutamide and abiraterone in
prostate cancer. N Engl J Med. 371:1028–1038. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zheng Z, Li J, Liu Y, Shi Z, Xuan Z, Yang
K, Xu C, Bai Y, Fu M, Xiao Q, et al: The crucial role of AR-V7 in
enzalutamide-resistance of castration-resistant prostate cancer.
Cancers. 14:48772022. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
You S, Knudsen BS, Erho N, Alshalalfa M,
Takhar M, Al-Deen Ashab H, Davicioni E, Karnes RJ, Klein EA, Den
RB, et al: Integrated classification of prostate cancer reveals a
novel luminal subtype with poor outcome. Cancer Res. 76:4948–4958.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhao SG, Chang SL, Erho N, Yu M, Lehrer J,
Alshalalfa M, Speers C, Cooperberg MR, Kim W, Ryan CJ, et al:
Associations of luminal and basal subtyping of prostate cancer with
prognosis and response to androgen deprivation therapy. JAMA Oncol.
3:1663–1672. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Myers JA and Miller JS: Exploring the NK
cell platform for cancer immunotherapy. Nat Rev Clin Oncol.
18:85–100. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang Y, Xiang Y, Xin VW, Wang XW, Peng XC,
Liu XQ, Wang D, Li N, Cheng JT, Lyv YN, et al: Dendritic cell
biology and its role in tumor immunotherapy. J Hematol Oncol.
13:1072020. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dhanasekaran R, Deutzmann A,
Mahauad-Fernandez WD, Hansen AS, Gouw AM and Felsher DW: The MYC
oncogene- the grand orchestrator of cancer growth and immune
evasion. Nat Rev Clin Oncol. 19:23–36. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Qiu X, Boufaied N, Hallal T, Feit A, de
Polo A, Luoma AM, Alahmadi W, Larocque J, Zadra G, Xie Y, et al:
MYC drives aggressive prostate cancer by disrupting transcriptional
pause release at androgen receptor targets. Nat Commun.
13:25592022. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Arriaga JM, Panja S, Alshalalfa M, Zhao J,
Zou M, Giacobbe A, Madubata CJ, Kim JY, Rodriguez A, Coleman I, et
al: A MYC and RAS co-activation signature in localized prostate
cancer drives bone metastasis and castration resistance. Nat
Cancer. 1:1082–1096. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Faskhoudi MA, Molaei P, Sadrkhanloo M,
Orouei S, Hashemi M, Bokaie S, Rashidi M, Entezari M, Zarrabi A,
Hushmandi K, et al: Molecular landscape of c-Myc signaling in
prostate cancer: A roadmap to clinical translation. Pathol Res
Pract. 233:1538512022. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Han Z, Mo R, Cai S, Feng Y, Tang Z, Ye J,
Liu R, Cai Z, Zhu X, Deng Y, et al: Differential expression of E2F
transcription factors and their functional and prognostic roles in
human prostate cancer. Front Cell Dev Biol. 10:8313292022.
View Article : Google Scholar : PubMed/NCBI
|
